Femasys, Inc. (FEMY)
|Net Income (ttm)||n/a|
|Day's Range||6.92 - 7.11|
|52-Week Range||6.50 - 13.75|
|Est. Earnings Date||Nov 10, 2021|
Femasys is a biomedical company focused on transforming women’s healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. As a woman-founded and led company with an expansive, internally created intellectual property portfolio with over 100 patents globally, in-house chemistry, manufacturing and controls, or CMC, and device manufacturing capabilities and proven ability to develop and commercialize products, we believe that we are well-positioned to be... [Read more...]
In 2020, Femasys's revenue was $1.04 million, an increase of 11.72% compared to the previous year's $929,064. Losses were -$6.91 million, -38.65% less than in 2019.Financial Statements
ATLANTA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally in...
ATLANTA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a biomedical company developing a suite of product candidates to transform women's healthcare with m...
-- Industry veteran with over than two decades of experience in medical affairs to lead clinical and medical affairs at Femasys -- ATLANTA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY)...
First in Class Insemination Treatment for Infertility
NEW YORK, June 21, 2021 /PRNewswire/ -- Chardan, a global investment bank, today announced that it acted as lead left bookrunner in the successful closing of the $34.45 million IPO of Femasys, Inc. (NAS...
Femasys Inc., a biomedical company focused on transforming women's healthcare by developing novel solutions...
Femasys, Inc. has filed to go public with an IPO on the NASDAQ.